These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21719338)

  • 1. [Pathogen inactivation in platelet concentrates: the French experience].
    Cazenave JP
    Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
    Lozano M; Cid J
    Transfus Clin Biol; 2013 May; 20(2):158-64. PubMed ID: 23587612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Photochemical inactivation of pathogens in platelets and plasma: five years of clinical use in routine and hemovigilance. Towards a change of paradigm in transfusion safety].
    Cazenave JP
    Transfus Clin Biol; 2011 Apr; 18(2):53-61. PubMed ID: 21474358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.
    Lin L; Dikeman R; Molini B; Lukehart SA; Lane R; Dupuis K; Metzel P; Corash L
    Transfusion; 2004 Oct; 44(10):1496-504. PubMed ID: 15383024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro photochemical inactivation of cell-associated human T-cell leukemia virus Type I and II in human platelet concentrates and plasma by use of amotosalen.
    Jauvin V; Alfonso RD; Guillemain B; Dupuis K; Fleury HJ
    Transfusion; 2005 Jul; 45(7):1151-9. PubMed ID: 15987361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model.
    Jordan CT; Saakadze N; Newman JL; Lezhava LJ; Maiers TT; Hillyer WM; Roback JD; Hillyer CD
    Transfusion; 2004 Aug; 44(8):1159-65. PubMed ID: 15265119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.
    Eastman RT; Barrett LK; Dupuis K; Buckner FS; Van Voorhis WC
    Transfusion; 2005 Sep; 45(9):1459-63. PubMed ID: 16131378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.
    Snyder E; McCullough J; Slichter SJ; Strauss RG; Lopez-Plaza I; Lin JS; Corash L; Conlan MG;
    Transfusion; 2005 Dec; 45(12):1864-75. PubMed ID: 16371039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the use of pathogen-reduced human plasma and platelet concentrates.
    Seltsam A; Müller TH
    Br J Haematol; 2013 Aug; 162(4):442-54. PubMed ID: 23710899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of the THERAFLEX UV-Platelets pathogen inactivation system - an update.
    Seghatchian J; Tolksdorf F
    Transfus Apher Sci; 2012 Apr; 46(2):221-9. PubMed ID: 22365926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pathogen inactivation in labile blood products: transfusion safety and economic impact].
    Cazenave JP
    Bull Acad Natl Med; 2006 Jan; 190(1):169-85; discussion 186-8. PubMed ID: 16878453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
    Corash L
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathogen reduction for platelets: available techniques and recent developments].
    Andreu G
    Transfus Clin Biol; 2011 Aug; 18(4):444-62. PubMed ID: 21724440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.
    Roback JD; Conlan M; Drew WL; Ljungman P; Nichols WG; Preiksaitis JK
    Transfus Med Rev; 2006 Jan; 20(1):45-56. PubMed ID: 16373187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bacterial contamination: should it be detected or inactivated?].
    Cazenave JP
    Transfus Clin Biol; 2007 May; 14(1):81-5. PubMed ID: 17521943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
    Sawyer L; Hanson D; Castro G; Luckett W; Dubensky TW; Stassinopoulos A
    Transfusion; 2007 Jun; 47(6):1062-70. PubMed ID: 17524098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.